MedTrace Logo

Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis

NCT03688971 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-05-01

No results posted yet for this study

Summary

To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.

Conditions

  • Seborrheic Dermatitis

Interventions

DRUG

Omiganan

Omiganan Topical Gel

DRUG

Ketoconazole

Ketoconazole Cream

DRUG

Placebo

Vehicle

Sponsors & Collaborators

  • Maruho Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Robert Rissmann, PhD · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-22
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688971 on ClinicalTrials.gov